{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:00:05Z","timestamp":1772006405318,"version":"3.50.1"},"reference-count":148,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biliary tract cancer (BTC) is a highly heterogeneous malignancy originating from the biliary epithelium or gallbladder mucosa, characterized by strong invasiveness and poor prognosis. Although surgery remains the primary curative strategy, most patients are diagnosed at advanced stages, limiting surgical opportunities. The traditional gemcitabine plus cisplatin chemotherapy regimen, although a standard treatment, has limited efficacy and often leads to drug resistance. In recent years, adoptive cell immunotherapy has emerged as a promising new avenue for BTC treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>This review systematically elaborates on the research progress of various ACT strategies in BTC, including chimeric antigen receptor T cells, tumor-infiltrating lymphocytes, natural killer cells, cytokine-induced killer cells, and T-cell receptor-engineered T cells. Furthermore, it comprehensively analyzes current key challenges and discusses future directions and optimization strategies regarding these therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This review summarizes recent progress in adoptive cell therapy for biliary tract cancer and discusses optimization strategies to facilitate clinical translation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1771318","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:04:00Z","timestamp":1772003040000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Overcoming heterogeneity and immunosuppression: novel strategies in adoptive therapy for biliary tract cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Yifan","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingcheng","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Affiliated Hospital of Jiangnan University","place":["Wuxi, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanchao","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12020234","article-title":"Environmental and lifestyle risk factors in the carcinogenesis of gallbladder cancer","volume":"12","author":"Perez-Moreno","year":"2022","journal-title":"J Pers Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.107064","article-title":"Epidemiology of cholangiocarcinoma","volume":"51","author":"Qurashi","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1384314","article-title":"Global, regional, and national burden and trends analysis of gallbladder and biliary tract cancer from 1990 to 2019 and predictions to 2030: A systematic analysis for the global burden of disease study 2019","volume":"11","author":"Su","year":"2024","journal-title":"Front Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.Epi-23-0562","article-title":"Temporal trends of stages and survival of biliary tract cancers in the United States and associations with demographic factors","volume":"32","author":"Wen","year":"2023","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000760","article-title":"Neoadjuvant and adjuvant therapy for biliary tract cancer: advances and limitations","volume":"82","author":"Wilbur","year":"2025","journal-title":"Hepatology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.04.038","article-title":"Metabolic reprogramming in cholangiocarcinoma","volume":"77","author":"Raggi","year":"2022","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00986-3","article-title":"The tumor microenvironment\u2019s role in the response to immune checkpoint blockade","volume":"6","author":"Aliazis","year":"2025","journal-title":"Nat Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jare.2024.05.031","article-title":"Unlocking the crucial role of cancer-associated fibroblasts in tumor metastasis: mechanisms and therapeutic prospects","volume":"71","author":"Liu","year":"2025","journal-title":"J Adv Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104003","article-title":"Esmo clinical practice guideline interim update on the management of biliary tract cancer","volume":"10","author":"Vogel","year":"2025","journal-title":"ESMO Open"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-24-0517","article-title":"Fda approval summary: durvalumab and pembrolizumab, immune checkpoint inhibitors for the treatment of biliary tract cancer","volume":"30","author":"Casak","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104388","article-title":"Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers","volume":"199","author":"Demir","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02236-9","article-title":"Multi-omic analysis of gallbladder cancer identifies distinct tumor microenvironments associated with disease progression","volume":"57","author":"Zhou","year":"2025","journal-title":"Nat Genet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/s12967-024-05206-7","article-title":"The potential and promise for clinical application of adoptive T cell therapy in cancer","volume":"22","author":"Li","year":"2024","journal-title":"J Transl Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific car T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02229","article-title":"Strive-02: A first-in-human phase I study of systemically administered B7-H3 chimeric antigen receptor T cells for patients with relapsed\/refractory solid tumors","volume":"42","author":"Pinto","year":"2024","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2022.2058149","article-title":"C-met specific car-T cells as a targeted therapy for non-small cell lung cancer cell A549","volume":"13","author":"Min","year":"2022","journal-title":"Bioengineered"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012885","article-title":"Reinfusion of cd19 car T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia","volume":"8","author":"Myers","year":"2024","journal-title":"Blood Adv"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101495","article-title":"Car-T cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2025.08.009","article-title":"Overcoming solid-tumor barriers: armored car-T cell therapy","volume":"11","author":"Kwon","year":"2025","journal-title":"Trends Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06243-w","article-title":"Car T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a jak-stat signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of car T-cell therapy","volume":"18","author":"Dejenie","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133476","article-title":"Fine-tuning through generations: advances in structure and production of car-T therapy","volume":"15","author":"Zheng","year":"2023","journal-title":"Cancers"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116619","article-title":"Tumor-associated carbohydrate antigens of muc1-implication in cancer development","volume":"174","author":"Radziejewska","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110091","article-title":"Muc1 induces the accumulation of foxp3(+) treg cells in the tumor microenvironment to promote the growth and metastasis of cholangiocarcinoma through the egfr\/pi3k\/akt signaling pathway","volume":"118","author":"Zhang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2010.08.004","article-title":"The expression of muc mucin in cholangiocarcinoma","volume":"206","author":"Mall","year":"2010","journal-title":"Pathol Res Pract"},{"key":"B31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/cji.0000000000000460","article-title":"Development of engineered car T cells targeting tumor-associated glycoforms of muc1 for the treatment of intrahepatic cholangiocarcinoma","volume":"46","author":"Mao","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"6276","DOI":"10.1038\/s41598-021-85747-9","article-title":"Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma","volume":"11","author":"Supimon","year":"2021","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.163","article-title":"Muc1 inhibition leads to decrease in pd-L1 levels via upregulation of mirnas","volume":"31","author":"Pyzer","year":"2017","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40164-024-00515-5","article-title":"Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of pd-1\/pd-L1 and regulatory pathways","volume":"13","author":"Wang","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.10.006","article-title":"Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing pd-1-cd28 switch receptor against cholangiocarcinoma cells","volume":"25","author":"Supimon","year":"2023","journal-title":"Cytotherapy"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae076","article-title":"Egfr, her2, and met gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance","volume":"29","author":"Kim","year":"2024","journal-title":"Oncologist"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2023.2218613","article-title":"Targeting the egfr signaling pathway in cancer therapy: what\u2019s new in 2023","volume":"27","author":"Halder","year":"2023","journal-title":"Expert Opin Ther Targets"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-17-0432","article-title":"Phase I study of chimeric antigen receptor-modified T cells in patients with egfr-positive advanced biliary tract cancers","volume":"24","author":"Guo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0378-7","article-title":"Cocktail treatment with egfr-specific and cd133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma","volume":"10","author":"Feng","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-023-01921-6","article-title":"Exploring the role of itgb6: fibrosis, cancer, and other diseases","volume":"29","author":"Zhang","year":"2024","journal-title":"Apoptosis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012346","article-title":"Integrin alpha V beta 6 (Av\u03b26) and its implications in cancer treatment","volume":"23","author":"Brzozowska","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153022","article-title":"Integrin Av\u03b26 predicts poor prognosis and promotes resistance to cisplatin in hilar cholangiocarcinoma","volume":"216","author":"Sun","year":"2020","journal-title":"Pathol Res Pract"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.657868","article-title":"Chimeric antigen receptor T cells targeting integrin Av\u03b26 expressed on cholangiocarcinoma cells","volume":"11","author":"Phanthaphol","year":"2021","journal-title":"Front Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1186\/s12967-025-06453-y","article-title":"Enhanced cytotoxicity against cholangiocarcinoma by fifth-generation chimeric antigen receptor T cells targeting integrin Av\u03b26 and secreting anti-pd-L1 scfv","volume":"23","author":"Phanthaphol","year":"2025","journal-title":"J Transl Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242417398","article-title":"Can cd133 be regarded as a prognostic biomarker in oncology: pros and cons","volume":"24","author":"Gisina","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i9.1192","article-title":"Strong expression of cd133 is associated with increased cholangiocarcinoma progression","volume":"17","author":"Leelawat","year":"2011","journal-title":"World J Gastroenterol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113588","article-title":"Loss of A-1,2-mannosidase man1c1 promotes tumorigenesis of intrahepatic cholangiocarcinoma through enhancing cd133-fip200 interaction","volume":"42","author":"Wei","year":"2023","journal-title":"Cell Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107069","article-title":"Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting cd133 against cholangiocarcinoma cells","volume":"89","author":"Sangsuwannukul","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/apm.12837","article-title":"B7-H3 expression and its correlation with clinicopathologic features, angiogenesis, and prognosis in intrahepatic cholangiocarcinoma","volume":"126","author":"Cheng","year":"2018","journal-title":"Apmis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701006","article-title":"B7-H3\/cd276: an emerging cancer immunotherapy","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000003099","article-title":"B7-H3 in acute myeloid leukemia: from prognostic biomarker to immunotherapeutic target","volume":"137","author":"Tan","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-23-1011","article-title":"Tbk1 targeting is identified as a therapeutic strategy to enhance car T-cell efficacy using patient-derived organotypic tumor spheroids","volume":"13","author":"Sun","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2018.07.622","article-title":"B7-H3-specific chimeric-antigen receptor T-cell-based immunotherapy for intrahepatic cholangiocarcinoma","volume":"227","author":"Kurokawa","year":"2018","journal-title":"J Am Coll Surg"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104471","article-title":"Advancements in tumor-infiltrating lymphocytes: historical insights, contemporary milestones, and future directions in oncology therapy","volume":"202","author":"Aizaz","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e2200204","DOI":"10.1002\/bies.202200204","article-title":"Tumor-infiltrating lymphocyte therapy: clinical aspects and future developments in this breakthrough cancer treatment","volume":"45","author":"Lee","year":"2023","journal-title":"Bioessays"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e005755","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (Til) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144\u201301 study","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41591-025-03627-5","article-title":"Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: A phase 2 trial","volume":"31","author":"Lowery","year":"2025","journal-title":"Nat Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e010207","DOI":"10.1136\/jitc-2024-010207","article-title":"Art of til immunotherapy: sitc\u2019s perspective on demystifying a complex treatment","volume":"13","author":"Turcotte","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e006303","DOI":"10.1136\/jitc-2022-006303","article-title":"Specific recognition of an fgfr2 fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma","volume":"11","author":"White","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific cd4+T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"key":"B61","doi-asserted-by":"publisher","first-page":"vkaf242","DOI":"10.1093\/jimmun\/vkaf242","article-title":"Development of a murine tumor-infiltrating lymphocyte therapy model for cholangiocarcinoma","volume":"215","author":"Wittling","year":"2026","journal-title":"J Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102349","article-title":"Therapeutic T cells with 3-in-1 strategy for the treatment of biliary tract cancer","volume":"6","author":"Wan","year":"2025","journal-title":"Cell Rep Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-24-1265","article-title":"Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a potential biomarker for immune checkpoint inhibitors in patients with biliary tract cancer","volume":"30","author":"Bang","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the nk cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01145-x","article-title":"Development of nk cell-based cancer immunotherapies through receptor engineering","volume":"21","author":"Page","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/s13287-024-04029-z","article-title":"Phenotypic and transcriptomic profiling of induced pluripotent stem cell (Ipsc)-derived nk cells and their cytotoxicity against cancers","volume":"15","author":"Thongsin","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11307","article-title":"In vivo study of natural killer (Nk) cell cytotoxicity against cholangiocarcinoma in a nude mouse model","volume":"32","author":"Jung","year":"2018","journal-title":"In Vivo"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/cells13161322","article-title":"Analysis of the effector functions of V\u03b42 \u0393\u03b4 T cells and nk cells against cholangiocarcinoma cells","volume":"13","author":"Kulma","year":"2024","journal-title":"Cells"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112273","article-title":"Precision immunotherapy for cholangiocarcinoma: pioneering the use of human-derived anti-cmet single chain variable fragment in anti-cmet chimeric antigen receptor (Car) nk cells","volume":"136","author":"Chiawpanit","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202508101","article-title":"Ultrasound-activated piezoelectric nanoparticles targeting and activating nk cells for tumor immunotherapy","volume":"37","author":"Zhang","year":"2025","journal-title":"Adv Mater"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174229","article-title":"Safety and efficacy of allogeneic natural killer cells in combination with pembrolizumab in patients with chemotherapy-refractory biliary tract cancer: A multicenter open-label phase 1\/2a trial","volume":"14","author":"Leem","year":"2022","journal-title":"Cancers"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-336321","article-title":"Dual-functional capability of cd3+Cd56+ Cik cells, a T-cell subset that acquires nk function and retains tcr-mediated specific cytotoxicity","volume":"118","author":"Pievani","year":"2011","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.9.3493.bloodjournal8693493","article-title":"Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced cd3+ Cd56+ Killer cells","volume":"86","author":"Mehta","year":"1995","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.731767","article-title":"Nkg2d engagement alone is sufficient to activate cytokine-induced killer cells while 2b4 only provides limited coactivation","volume":"12","author":"Wu","year":"2021","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40880-015-0002-1","article-title":"Cytokine-induced killer (Cik) cells: from basic research to clinical translation","volume":"34","author":"Guo","year":"2015","journal-title":"Chin J Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1080\/07357900802189832","article-title":"Human cytokine-induced killer cells specifically infiltrated and retarded the growth of the inoculated human cholangiocarcinoma cells in scid mice","volume":"27","author":"Wongkajornsilp","year":"2009","journal-title":"Cancer Invest"},{"key":"B78","article-title":"Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro","volume":"32","author":"Morisaki","year":"2012","journal-title":"Anticancer Res"},{"key":"B79","article-title":"Nkg2d-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors","volume":"34","author":"Morisaki","year":"2014","journal-title":"Anticancer Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1080\/07357900802239124","article-title":"Inducible costimulator (Icos) enhances the cytolytic activity of cytokine-induced killer cells against gallbladder cancer in vitro and in vivo","volume":"27","author":"Wang","year":"2009","journal-title":"Cancer Invest"},{"key":"B81","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1751-2980.2011.00527.x","article-title":"Immunomodulation of Inducible Co-Stimulator (Icos) in Human Cytokine-Induced Killer Cells against Cholangiocarcinoma through Icos\/Icos Ligand Interaction","volume":"12","author":"He","year":"2011","journal-title":"J Dig Dis"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S333604","article-title":"Complete response to pd-1 inhibitor in primary hepatocellular carcinoma patients post-progression on bi-specific antibody conjugated cik cell treatment: A report of two cases","volume":"14","author":"Wu","year":"2021","journal-title":"Onco Targets Ther"},{"key":"B83","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40164-024-00504-8","article-title":"Novel insights into tcr-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy","volume":"13","author":"Shao","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1190883","article-title":"Cancer\/testis antigens: promising immunotherapy targets for digestive tract cancers","volume":"14","author":"Ai","year":"2023","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02128-z","article-title":"Autologous T cell therapy for mage-A4(+) solid cancers in hla-a*02(+) patients: A phase 1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Nat Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-30-2","article-title":"Expression and prognostic significance of cancer-testis antigens (Cta) in intrahepatic cholagiocarcinoma","volume":"30","author":"Zhou","year":"2011","journal-title":"J Exp Clin Cancer Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1524629","article-title":"Generation of effective and specific human tcrs against tumor\/testis antigen ny-eso-1 in mice with humanized T cell recognition system","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-23-1456","article-title":"Safety and efficacy of ny-eso-1 antigen-specific T-cell receptor gene-transduced T lymphocytes in patients with synovial sarcoma: A phase I\/ii clinical trial","volume":"29","author":"Kawai","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-024-03249-w","article-title":"Ny-eso-1-specific T cell receptor-engineered T cells and tranilast, a trpv2 antagonist bivalent treatment enhances the killing of esophageal cancer: A dual-targeted cancer therapeutic route","volume":"24","author":"Amissah","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001775","article-title":"A tcr targeting the hla-a*0201-restricted epitope of mage-A3 recognizes multiple epitopes of the mage-a antigen superfamily in several types of cancer","volume":"186","author":"Chinnasamy","year":"2011","journal-title":"J Immunol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.canlet.2010.01.019","article-title":"Alpha-fetoprotein producing cells act as cancer progenitor cells in human cholangiocarcinoma","volume":"294","author":"Ishii","year":"2010","journal-title":"Cancer Lett"},{"key":"B92","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-024-01792-6","article-title":"A novel engineered il-21 receptor arms T-cell receptor-engineered T cells (Tcr-T cells) against hepatocellular carcinoma","volume":"9","author":"Zhu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.07.033","article-title":"Phase I trial of adp-A2afp tcr T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma","volume":"84","author":"Meyer","year":"2026","journal-title":"J Hepatol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00607","article-title":"Preclinical studies of the off-target reactivity of afp158-specific tcr engineered T cells","volume":"11","author":"Cai","year":"2020","journal-title":"Front Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.2547","article-title":"Safety and efficacy of sleeping beauty tcr-T cells targeting shared kras and tp53 mutations expressed by solid tumors in first-in-human phase 1 study","volume":"41","author":"Morelli","year":"2023","journal-title":"J Clin Oncol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41568-024-00761-z","article-title":"Convergent inducers and effectors of T cell paralysis in the tumour microenvironment","volume":"25","author":"Hanahan","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.01.009","article-title":"Metabolic programming and immune suppression in the tumor microenvironment","volume":"41","author":"Arner","year":"2023","journal-title":"Cancer Cell"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1097\/ot9.0000000000000063","article-title":"Remodeling tumor-associated macrophages in the tumor microenvironment","volume":"10","author":"Chen","year":"2024","journal-title":"Oncol Trans Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-11-0351","article-title":"Expression of a functional ccr2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00702","article-title":"Prolonged persistence of chimeric antigen receptor (Car) T cell in adoptive cancer immunotherapy: challenges and ways forward","volume":"11","author":"Jafarzadeh","year":"2020","journal-title":"Front Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.11.014","article-title":"Tumor-infiltrating lymphocyte therapy: A new frontier","volume":"31","author":"Tseng","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B103","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41419-022-04882-x","article-title":"Cd4+ T cells are required to improve the efficacy of cik therapy in non-small cell lung cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Cell Death Dis"},{"key":"B104","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/cji.0000000000000110","article-title":"Preparation of cytokine-activated nk cells for use in adoptive cell therapy in cancer patients: protocol optimization and therapeutic potential","volume":"39","author":"van Ostaijen-ten Dam","year":"2016","journal-title":"J Immunother"},{"key":"B105","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41392-023-01708-w","article-title":"Trogocytosis of car molecule regulates car-T cell dysfunction and tumor antigen escape","volume":"8","author":"Zhai","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117252","article-title":"Antigen escape in car-T cell therapy: mechanisms and overcoming strategies","volume":"178","author":"Lin","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-24-1383","article-title":"Generation of a biliary tract cancer cell line atlas identifies molecular subtypes and therapeutic targets","volume":"15","author":"Vijay","year":"2025","journal-title":"Cancer Discov"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-22-1954","article-title":"Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention","volume":"28","author":"Giraldo","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00529-8","article-title":"Masking T cell engagers mitigates on-target off-tumor activity","volume":"4","author":"Silver","year":"2023","journal-title":"Nat Cancer"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1177\/1533034615578959","article-title":"Prognostic value of C-met expression in cholangiocarcinoma","volume":"15","author":"Mao","year":"2016","journal-title":"Technol Cancer Res Treat"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1273507","article-title":"Prediction of severe crs and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with car-T cells","volume":"14","author":"Wei","year":"2023","journal-title":"Front Immunol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (Car) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-00850-9","article-title":"Il-2 regulates tumor-reactive cd8(+) T cell exhaustion by activating the aryl hydrocarbon receptor","volume":"22","author":"Liu","year":"2021","journal-title":"Nat Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/0753-3322(92)90005-r","article-title":"Current status of interleukin-2 therapy in cancer","volume":"46","author":"Tartour","year":"1992","journal-title":"BioMed Pharmacother"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0603272","article-title":"The main function of il-2 is to promote the development of T regulatory cells","volume":"74","author":"Malek","year":"2003","journal-title":"J Leukoc Biol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-004747","article-title":"Il-2 regulates foxp3 expression in human cd4+Cd25+ Regulatory T cells through a stat-dependent mechanism and induces the expansion of these cells in vivo","volume":"108","author":"Zorn","year":"2006","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200526230","article-title":"Hla type-independent generation of antigen-specific T cells for adoptive immunotherapy","volume":"35","author":"Hammer","year":"2005","journal-title":"Eur J Immunol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"e012029","DOI":"10.1136\/jitc-2025-012029","article-title":"Integrated system for screening tumor-specific tcrs, epitopes, and hla subtypes using single-cell sequencing data","volume":"13","author":"Wang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B119","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/cac2.12452","article-title":"Enhancement of car-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins","volume":"43","author":"Qiao","year":"2023","journal-title":"Cancer Commun (Lond)"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09212-7","article-title":"Rewiring endogenous genes in car T cells for tumour-restricted payload delivery","volume":"644","author":"Chen","year":"2025","journal-title":"Nature"},{"key":"B121","doi-asserted-by":"publisher","first-page":"e1378842","DOI":"10.1080\/2162402x.2017.1378842","article-title":"Intra-tumoral production of il18, but not il12, by tcr-engineered T cells is non-toxic and counteracts immune evasion of solid tumors","volume":"7","author":"Kunert","year":"2017","journal-title":"Oncoimmunology"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102353","article-title":"Car-T cells in solid tumors: challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"B124","doi-asserted-by":"publisher","first-page":"e2405085121","DOI":"10.1073\/pnas.2405085121","article-title":"Dual on\/off-switch chimeric antigen receptor controlled by two clinically approved drugs","volume":"121","author":"Giordano Attianese","year":"2024","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B125","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1186\/s13046-023-02838-3","article-title":"Cd276-car T cells and dual-car T cells targeting cd276\/fgfr4 promote rhabdomyosarcoma clearance in orthotopic mouse models","volume":"42","author":"Timpanaro","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-025-01701-6","article-title":"Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects","volume":"18","author":"Qin","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12916-024-03420-0","article-title":"Il-2-free tumor-infiltrating lymphocyte therapy with pd-1 blockade demonstrates potent efficacy in advanced gynecologic cancer","volume":"22","author":"Guo","year":"2024","journal-title":"BMC Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to cd19-directed car T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-022-00543-5","article-title":"Rational pemetrexed combined with cik therapy plus anti-pd-1 mabs administration sequence will effectively promote the efficacy of cik therapy in non-small cell lung cancer","volume":"30","author":"Liu","year":"2023","journal-title":"Cancer Gene Ther"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2017.5305","article-title":"Low dose irradiation increases adoptive cytotoxic T lymphocyte migration in gastric cancer","volume":"14","author":"Du","year":"2017","journal-title":"Exp Ther Med"},{"key":"B131","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","article-title":"Low-dose irradiation programs macrophage differentiation to an inos+\/M1 phenotype that orchestrates effective T cell immunotherapy","volume":"24","author":"Klug","year":"2013","journal-title":"Cancer Cell"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102282","article-title":"Multiplexed ipsc platform for advanced nk cell immunotherapies","volume":"6","author":"Kumar","year":"2025","journal-title":"Cell Rep Med"},{"key":"B133","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13045-019-0788-4","article-title":"Tcr-like antibodies in cancer immunotherapy","volume":"12","author":"He","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1038\/s41467-024-47062-5","article-title":"The physiological interactome of tcr-like antibody therapeutics in human tissues","volume":"15","author":"Marrer-Berger","year":"2024","journal-title":"Nat Commun"},{"key":"B135","doi-asserted-by":"publisher","first-page":"e14073","DOI":"10.15252\/emmm.202114073","article-title":"Modulation of intrinsic inhibitory checkpoints using nano-carriers to unleash nk cell activity","volume":"14","author":"Biber","year":"2022","journal-title":"EMBO Mol Med"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.2c03311","article-title":"Enhancing adoptive cell therapy by T cell loading of shp2 inhibitor nanocrystals before infusion","volume":"16","author":"Li","year":"2022","journal-title":"ACS Nano"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.2c11884","article-title":"Direct in vivo activation of T cells with nanosized immunofilaments inhibits tumor growth and metastasis","volume":"17","author":"Weiss","year":"2023","journal-title":"ACS Nano"},{"key":"B138","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mrna nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat Commun"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.4c17899","article-title":"Tumor microenvironment-responsive nano-immunomodulators for enhancing chimeric antigen receptor-T cell therapy in lung cancer","volume":"19","author":"Chen","year":"2025","journal-title":"ACS Nano"},{"key":"B140","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.3390\/ijms19102885","article-title":"The role of stroma in cholangiocarcinoma: the intriguing interplay between fibroblastic component, immune cell subsets and tumor epithelium","volume":"19","author":"Gentilini","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2019.10.005","article-title":"Fibroblastic fap promotes intrahepatic cholangiocarcinoma growth via mdscs recruitment","volume":"21","author":"Lin","year":"2019","journal-title":"Neoplasia"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1172681","article-title":"Stromal depletion by talen-edited universal hypoimmunogenic fap-car T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted car-T immunotherapy","volume":"14","author":"Das","year":"2023","journal-title":"Front Immunol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-023-01308-9","article-title":"Targeting fibroblast activation protein (Fap): advances in car-T cell, antibody, and vaccine in cancer immunotherapy","volume":"13","author":"Shahvali","year":"2023","journal-title":"Drug Delivery Transl Res"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117080","article-title":"Tumor-infiltrating T lymphocytes: A promising immunotherapeutic target for preventing immune escape in cholangiocarcinoma","volume":"177","author":"Hua","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B145","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","article-title":"Pluripotent stem cell-derived car-macrophage cells with antigen-dependent anti-cancer cell functions","volume":"13","author":"Zhang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"Car-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01387-8","article-title":"Targeting inflammation with chimeric antigen receptor macrophages using a signal switch","volume":"9","author":"Cao","year":"2025","journal-title":"Nat BioMed Eng"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102307","article-title":"Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity","volume":"6","author":"Xiao","year":"2025","journal-title":"Cell Rep Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1771318\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:04:01Z","timestamp":1772003041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1771318\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":148,"alternative-id":["10.3389\/fimmu.2026.1771318"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1771318","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"article-number":"1771318"}}